Precision BioSciences (Nasdaq:DTIL) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

DTIL Overzicht aandelen

Precision BioSciences, Inc., een geavanceerd gen editing bedrijf, ontwikkelt in vivo gen editing therapieën voor gen edits, inclusief gen eliminatie, insertie en excisie in de Verenigde Staten.

Over het bedrijf

DTIL fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	0/6
Prestaties in het verleden	4/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

De koers-winstverhouding ( 4.2 x) ligt onder de US markt ( 18.3 x)

Dit jaar winstgevend geworden

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

De winst zal naar verwachting de komende drie jaar met gemiddeld 43.7% per jaar dalen.

Heeft geen betekenisvolle marktkapitalisatie ( $65M )

Precision BioSciences, Inc. Concurrenten

Eagle Pharmaceuticals

NasdaqGM:EGRX

US$48.4m

Puma Biotechnology

NasdaqGS:PBYI

US$125.1m

Inhibrx Biosciences

NasdaqGS:INBX

US$226.7m

CytomX Therapeutics

NasdaqGS:CTMX

US$92.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Precision BioSciences
Historische aandelenkoersen
Huidige aandelenkoers	US$9.10
52 Week Hoogtepunt	US$19.43
52 Week Laag	US$8.25
Bèta	1.69
11 maand verandering	-16.36%
3 maanden verandering	-1.94%
1 Jaar Verandering	-5.80%
33 jaar verandering	-97.29%
5 jaar verandering	-95.96%
Verandering sinds IPO	-98.26%

Recent nieuws en updates

Recent updates

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Aug 06

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Jun 23

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Dec 08

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Sep 02

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Apr 19

Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)

Mar 21

Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely

Dec 31

Precision BioSciences: Uniquely Positioned

Oct 07

Is Precision BioSciences (NASDAQ:DTIL) A Risky Investment?

Sep 24

Precision BioSciences: The Right Profile To Progress

Aug 27

Rendement voor aandeelhouders

	DTIL	US Biotechs	US Markt
7D	-1.0%	-0.2%	-0.4%
1Y	-5.8%	22.1%	34.1%

Rendement versus industrie: DTIL presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 21.7 % opleverde.

Rendement versus markt: DTIL presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 33.4 % opleverde.

Prijsvolatiliteit

Is DTIL's price volatile compared to industry and market?
DTIL volatility
DTIL Average Weekly Movement	6.5%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: DTIL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van DTIL is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2006	110	Michael Amoroso	www.precisionbiosciences.com

Precision BioSciences, Inc., een geavanceerd gen editing bedrijf, ontwikkelt in vivo gen editing therapieën voor gen edits, inclusief gen eliminatie, insertie en excisie in de Verenigde Staten. Het bedrijf biedt ARCUS, een genoom editing platform voor DNA genoom insertie, deletie en reparatie. Het biedt ook PBGENE-HBV voor de behandeling van chronisch hepatitis B-virus (HBV) om covalent gesloten circulair DNA te elimineren met directe cuts en edits en om geïntegreerd HBV-DNA te inactiveren met als doel langdurige reducties in hepatitis B-oppervlakteantigeen; PBGENE-PMM voor de behandeling van m.3243-geassocieerde primaire mitochondriale myopathie (PMM) waarvoor naar verwachting een IND en/of CTA zal worden ingediend.

Precision BioSciences, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Precision BioSciences zich tot de beurswaarde?
DTIL fundamentele statistieken
Marktkapitalisatie	US$64.81m
Inkomsten(TTM)	US$15.79m
Inkomsten(TTM)	US$87.64m

4.2x

Koers/Winstverhouding

0.8x

P/S-verhouding

Is DTIL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DTIL resultatenrekening (TTM)
Inkomsten	US$87.64m
Kosten van inkomsten	US$0
Brutowinst	US$87.64m
Overige uitgaven	US$71.85m
Inkomsten	US$15.79m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	2.18
Brutomarge	100.00%
Nettowinstmarge	18.02%
Schuld/Eigen Vermogen Verhouding	30.1%

Hoe presteerde DTIL op de lange termijn?

Bekijk historische prestaties en vergelijking

DTIL Overzicht aandelen

Beloningen

Risicoanalyse

Precision BioSciences, Inc. Concurrenten

NasdaqGM:EGRX

US$48.4m

NasdaqGS:PBYI

US$125.1m

NasdaqGS:INBX

US$226.7m

NasdaqGS:CTMX

US$92.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Precision BioSciences, Inc Announces Executive Changes Changes

Precision BioSciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress

Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Precision BioSciences, Inc., Annual General Meeting, Jun 04, 2024

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Recent updates

Precision BioSciences, Inc Announces Executive Changes Changes

Precision BioSciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress

Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Precision BioSciences, Inc., Annual General Meeting, Jun 04, 2024

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Precision BioSciences, Inc. has filed a Follow-on Equity Offering.

Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness

Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.

Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure

Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Precision BioSciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Price target decreased by 15% to US$2.60

Precision BioSciences, Inc. Announces Management Changes

Consensus revenue estimates increase by 47%

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Price target decreased by 24% to US$5.07

Precision Biosciences, Inc. Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of in Vivo R&D Day

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision Biosciences, Inc. Announces Oral Presentation of Positive Arcus Gene Editing Data At International Liver Congress 2023

Precision Biosciences, Inc. Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at American Society of Gene & Cell Therapy 26th Annual Meeting

Consensus revenue estimates increase by 17%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 27%

Price target decreased by 11% to US$6.00

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, Its Lead Allogeneic Car T Clinical Candidate

Precision BioSciences, Inc. Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Less than half of directors are independent

Price target decreased to US$6.63

Precision BioSciences, Inc. Announces Raymond Schinazi Resigns from Board and as Chair of Nominating and Corporate Governance Committee and Member of Compensation Committee and Science and Technology Committee

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Financial Officer recently bought US$60k worth of stock

Precision BioSciences, Inc Announces Executive Promotions

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Precision BioSciences Q2 2022 Earnings Preview

Precision BioSciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Precision BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from Russell 2000 Dynamic Index

Chief Financial Officer recently bought US$51k worth of stock

Consensus forecasts updated

Price target decreased to US$10.63

Precision BioSciences, Inc. Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

Precision Biosciences, Inc. Appoints Melinda Brown to its Board of Directors and Chair of the Board’s Audit Committee

Precision BioSciences, Inc. Appoints Juli Blanche as Chief People Officer